|
|
本帖最后由 douban 于 2016-8-27 12:00 编辑
& e6 ]# b1 f/ e0 |: f& L- ]9 g" G7 H7 R- z* R2 i, C
Development of Novel Vaccines
) `! G$ b$ V9 `8 L" Q: p3 @, [& v& G |0 [; }5 m, S0 H
Skills, Knowledge and Translational Technologies! ~# U! V) @( G7 O" L) m0 Y; _
, f3 M$ Z: \9 \/ f6 EEditors: von Gabain, Alexander, Klade, Christoph (Eds.)
& e0 \/ @9 R% y( P) r b" y& J8 b" O- [6 i$ r5 F- B% Z1 _
) `# r1 x" [' ~4 c" W: u$ w, X" i6 b$ ~. T
About this book
- i3 E6 r9 _. R! c8 D) x! B6 h5 F; T$ H
“Development of novel vaccines” gives an overview of the tasks in basic research leading to the final product – the vaccine and its applications, belonging to the most complex biologics in the pharmaceutical field. Distinct from most textbooks in the vaccine arena, the current issue focuses on the translational aspect, namely, how research results can be transformed into life-saving medical interventions. Each chapter of the book deals with one important paradigm for the development of novel vaccines, along the value chain towards the final vaccine, and furthermore, with the inevitable tools required for this process. Contributions are prepared by teams of scientists, all of whom are experts in the field, most of them anchored in biomedical organizations devoted to translational culture, thereby lighting the certain topics from different views. This volume is a must read for researchers engaged in vaccine development and who really want to see their research results to become a product.
; ]% P3 ?5 e$ w0 x# b
9 E5 o$ }+ U; d" d1 f" j
- R8 A/ m$ \6 N' C' k6 k2 xTable of contents (11 chapters), Q; P* q, A5 b& @
# y* j1 K) d. P! L3 o/ }; L
% ~: s% G/ a1 a7 C- `: [6 gSkills, Knowledge, and Translational Technologies Leading to Novel Vaccines
# s/ C9 }7 s$ }0 x4 T8 P, \! ?
! C: h7 x) n, BAlkan, Şefik Ş.
8 ^& v( o H$ I" S- f. F- L: O6 Q4 |. f- _& q- T, P Y4 w. G0 S
Pages 1-26
4 e# j9 h- [7 x/ @# ?8 d
% W4 X3 }1 U+ q" V, ZFinding Protective Bacterial Antigens L0 B" L; F6 A! X) e1 O* E
1 Q6 f4 j; m! n
Grandi, Guido (et al.)7 W* F1 e2 }& }3 B
5 W' _0 e( s: d- Z9 y* N
Pages 27-446 x$ j& |, x! |" ?( f( r
) Z+ i! X8 L. E
' Q1 E- ^- W3 W# R: B
Enhancing and Tailoring the Immunogenicity of Vaccines with Novel Adjuvants
, l+ u1 a$ @# C. ?$ n9 e& f8 j/ \+ ?" V6 O' i: Z, O/ K
Fox, Christopher B. (et al.)( B& p7 \' B. p) u# y; l: o
8 F7 Q( l* M5 j: @Pages 45-72. C" O4 J U3 [$ f, T9 B9 }
4 t0 \5 ^' b' p. J. i
/ v8 F! K4 |- G/ N0 u U( ]7 g# ?5 W$ e& n
Vaccine Delivery: Beyond Needles& I% V1 [6 J5 a
: r6 K4 F" a. D
Flyer, David C. (et al.)
0 [4 |' I7 u6 o) Z' H
" E. K- t" |& e1 _& U9 l- _Pages 73-86 }4 P! n2 J6 H
( C4 S# k2 Z. ?- l2 G
& n! J; [$ p: T, F5 [! m- v
) b2 ^* A' T3 N6 lEmploying Live Microbes for Vaccine Delivery- e5 a- S. E& n. ?
\( g( `$ h- `2 z* ]% }Loessner, Holger (et al.)' [: K7 x0 P! _% _- T9 n
: A8 Y4 C# {: K3 y2 C) Z, \4 fPages 87-124
9 i. C/ P* u; w4 A3 g) B4 k2 b; v
) U) `- P( ^) y: X1 F
; V) ~1 q- [ w+ l0 e9 K
Synthesizing Vaccines with Microbes, w/ ^" I: o' b) p) H! ]- G
+ P8 g1 i& \" d8 z7 x
Wacker, Michael (et al.)
1 n! G( C* T S: U. n! Y X4 K" ~# j X1 n" v
Pages 125-1440 u3 V4 W8 s, }7 ^* d) n
3 l, f0 k$ q# J7 M( H6 _( [+ I. E. ?# d
2 j/ ?/ h" z& _$ R2 q
Purification and Formulation: Silent but Important Players in Vaccine Development
4 c6 i+ x/ s$ U4 s( A) L8 y6 e- Y
6 e3 q6 S8 h! U" u2 V* lSchlegl, Robert (et al.)0 K% R, A& L1 B( {& O
& e+ H; S: \. _; \$ u; HPages 145-188
# @. R- U( E7 p5 h0 _" h' V! h# h8 b; K1 d3 \9 N* b' g
" Y) N: \4 h! V
. p8 `9 |0 U8 p. zCutting-Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines( k, q6 |8 M' z6 I/ }
7 |6 { l$ Z( @: e* `Arnon, Ruth (et al.); N0 T+ U) ]) K! h2 J$ d3 R( ]. m
: e$ M- n9 |) N, lPages 189-2048 v {( p* C! Q5 P6 `' K
) W; Z# C+ c' i+ k- _( z( D; I( S! z/ Z* z
( b3 J$ D; q4 e6 ^# j6 g
Cutting Edge Approaches Toward Novel and Cross-Protective Influenza Vaccines2 H" T1 ^( {7 U/ b
( ^: e: C7 A6 P1 t* V2 a$ d [
Roose, Kenny (et al.)
+ d; D+ P: k( I
1 r/ p) L k, Z1 ^Pages 205-232& N$ N9 R7 F) a& F6 A
2 z7 w1 r0 S1 B! R* {4 M8 b5 O* B
; ^; e" p ]0 _; i$ q4 H
7 B- g8 x$ Z0 L) c& n. P; VExamples of Novel Registered Prophylactic Vaccines, HPV, and JEV( X/ d" }2 ?6 b1 \* a
6 G- B! V/ f) C1 p+ z4 nDubischar-Kastner, Katrin (et al.)9 w* i- `1 p- w5 s6 Y
0 O1 G- f& u' Y7 F& E3 p- a
Pages 233-286, O/ `# a# M5 U) C; r
: w9 O0 F# s% G3 K' i9 z) C7 C3 |# Z
! D+ \8 V# b2 Y
The Bumpy Road Toward Vaccine Registration: How to Overcome Regulatory Hurdles! U7 Y1 T$ D$ M- H8 {# r" ~
5 R, C4 B! c/ L4 O! @$ bPfleiderer, Michael2 H+ E2 p- I; o0 w# ]
6 S7 ~3 W2 A1 q. R
Pages 287-300% I6 l6 q8 F7 h9 i/ a0 h; W6 n
6 O1 \8 I8 ~- r1 {( V+ P- f下载链接：2 B0 d4 R/ a: M7 B$ \! I
: G, b+ I5 }$ \+ | |
本帖子中包含更多资源
您需要 登录 才可以下载或查看，没有帐号？立即注册
x
评分
-
查看全部评分
|
发表于 2016-8-27 11:57:27
QQ好友和群
QQ空间
腾讯微博
腾讯朋友
收藏
分享
支持
反对
发表于 2016-8-27 12:54:55
